Company intelligence / Profile preview
Postsurgical Therapeutics
Irvine, California, United States
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Postsurgical Therapeutics has demonstrated in vivo efficacy of its sustained-release injectable gel (PLGA-based) delivering combined MEK and mTOR inhibitors, achieving tumor suppression or eradication in murine models of multiple KRAS-mutant cancers. The company has additional pain programs in development, but public data indicates preclinical stage for all programs.[3][4]
- Therapeutic areas
- OncologyHematologyNeurology
- Modalities
- Small moleculePoly(lactic-co-glycolic acid) (PLGA) microsphereInjectable gelDrug delivery system
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Upex-Med
Beyond the preview
Go deeper on Postsurgical Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Postsurgical Therapeutics.